OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

just upped my holding again in this company can it get any worse???????

I only kept my profit in after the last rise so I'm not too worried, another dip & I'll put some more in again.

It will only take 1 of their drugs to succeed in trials to make this a BIG winner. If the first one to finish trials doesn't work then this will drop like a stone & provide an excellent buying opportunity to benefit from the success of the others.

Increased trading today, good or bad?!

An 18.7 Million trade at the mid price.

Interesting.

Over 2.5 Million quids worth.

Looks as though an end game one way or the other is developing!
This is purely guesswork on my part but with increased news flow that is flying around concerning TroVax I believe that the big boys are moving in and the 18.7M B trade is a BUY!!
This one has bottomed and will now head north. Again just my opinion.

should have added that will head north after boring the pants off people first!! once again sp hits snooze button.

DSTOREY9916

Look again.

UP 6.56% so far today.

Up 13% (my lucky number) and the wife has to take me shopping - keep it going while I am away. Good luck to you all.

Now UP 18%

:-)

And now heading south, are well!!

Looks as those all that activity has come to a grinding halt!!
So should sp retreat be a further buying opportunity or was this merely a false dawn?

It's Bid Speculation and why not at this price, someones bought a stake and we'll find out over next few days who, and then we should see some price improvement, and maybe a bid? Do the Majority s'holders - kingsman and family still have overall majority control? It would have to be an agreed bid I think.

robstuff, what bid speculation?

It seems to be up because of a licence aggreement.

17/09/04 07:00 License Agreement RNS

It looks like the big buyer knew about it 2 days ago, giving them an unfair advantage.

OXFORD BIOMEDICA SIGNS LICENSE AGREEMENT WITH MASSACHUSETTS GENERAL HOSPITAL, BOSTON UNIVERSITY AND DANA-FARBER CANCER INSTITUTE

Oxford BioMedica (LSE: OXB), the cancer and neurobiological gene therapy company, announced today that it has signed an agreement with Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute extending the field of Oxford BioMedicas exclusive access to the family of cytochrome P450 enzymes in cancer gene therapy. The P450 enzyme is used in Oxford BioMedicas novel cancer gene therapy product, MetXia. The extension of the license covers the development of MetXia as a treatment for pancreatic cancer.

Under a separate agreement, Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute have subscribed for a total of 352,887 ordinary shares of 1p each at 15.78 pence per share.

The P450 enzyme is naturally expressed in the liver and activates the chemotherapeutic drug cyclophosphamide. By delivering a specific P450 gene, MetXia promotes activation of cyclophosphamide directly in the tumour and thereby enhances its potency as an anti-tumour treatment. Oxford BioMedica licensed the rights to the P450 enzyme for cancer gene therapy from Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute in 1997 and extended the agreement previously in 2000.

Oxford BioMedica has demonstrated proof of concept with MetXia in two Phase I/II trials in patients with accessible tumours, primarily in breast cancer. In April 2004, the Company reported that recruitment had started in a Phase I trial, rolling into a Phase II trial in patients with pancreatic cancer. The safety stage of this trial is on-track to complete by the end of the year.

Oxford Biomedica PLC
17 September 2004

Oxford BioMedica plc (the 'Company')

Notification of Major Interests in Shares

The Company has received two notifications from Calyon Corporate and Investment
Bank on 16 & 17 September 2004 on behalf of Credit Agricole Cheuvreux
International Ltd.

The first informing it that they have an interest in 18,702,000 shares
representing 5.03% of the issued share capital and the second informing it that
they now have and interest in 18,552,000 shares representing 4.99% of the issued
shares capital of the Company which currently stands at 371,961,736 shares.

Andrew Wood
Chief Financial Officer
Tel 01865 783000

Very interesting stuff! Looks as though big boys are positioning themselves for future announcements/sp re-valuation.

Makes me glad that I left my profit in after the previous rise, pity that I didn't leave it all in.

:-)

So the big buyer I saw on Wednesday was Credit Agricole Cheuvreux International Ltd.

Apple, you want too hazard a guess as too what price OXB will reach year end if newsflow is as predicted?

can u guess?

I wouldn't dare!